{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:43:22Z","timestamp":1648723402939},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/mjt.0b013e318293b269","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T15:44:45Z","timestamp":1381160685000},"page":"e6-e7","source":"Crossref","is-referenced-by-count":2,"title":["Thalidomide-Induced Hemorrhagic Rash in a Patient With Myelofibrosis and Delta-Granule Storage Pool Disease"],"prefix":"10.1097","volume":"22","author":[{"given":"Asma","family":"Taj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Abbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland T.","family":"Skeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210202","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":". Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-17-20210202","first-page":"177","article-title":"Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations.","volume":"46","author":"Zwingenberger","year":"1995","journal-title":"J Inflamm"},{"key":"R3-17-20210202","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":". Thalidomide therapy for myelofibrosis with myeloid metaplasia.","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"R4-17-20210202","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":". Lenalidomide therapy in myelofibrosis with myeloid metaplasia.","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"R5-17-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0753-3322(02)00177-4","article-title":"Thalidomide, an antiangiogenic agent with clinical activity in cancer.","volume":"56","author":"Ng","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"R6-17-20210202","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2003.87","article-title":". Dermatologic side effects of thalidomide in patients with multiple myeloma.","volume":"48","author":"Hall","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R7-17-20210202","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJM200009283431315","article-title":"Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.","volume":"343","author":"Rajkumar","year":"2000","journal-title":"N Engl J Med"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e318293b269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:38:01Z","timestamp":1620963481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201501000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318293b269","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}